Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (797 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
A group of hereditary disorders involving tissues and structures derived from the embryonic ectoderm. They are characterized by the presence of abnormalities at birth and involvement of both the epidermis and skin appendages. They are generally nonprogressive and diffuse. Various forms exist, including anhidrotic and hidrotic dysplasias, focal dermal hypoplasia, and aplasia cutis congenita.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Dysplasia, Ectodermal; Dysplasias, Ectodermal; Ectodermal Dysplasias; Congenital Ectodermal Defect; Congenital Ectodermal Defects; Defects, Congenital Ectodermal; Ectodermal Defects, Congenital; Defect, Congenital Ectodermal.
Where it fits in the MeSH classification
- Broader topics
- Abnormalities, Multiple; Skin Abnormalities; Skin Diseases, Genetic
- Narrower topics
- Ectodermal Dysplasia 1, Anhidrotic; Ectodermal Dysplasia 3, Anhidrotic; Ectodermal Dysplasia, Hypohidrotic, Autosomal Recessive; Ellis-Van Creveld Syndrome; Focal Dermal Hypoplasia; Focal Facial Dermal Dysplasias; Neurocutaneous Syndromes; Pachyonychia Congenita
Related concepts
- Focal Dermal Hypoplasia
Research landscape
PubMed indexes 6,490 records tagged with the MeSH heading “Ectodermal Dysplasia” (counts retrieved 2026-10-29). 998 of them (15.4%) were published from 2020 onward, and the busiest period so far is through 1999 with 2,093 records.
Reviews account for 820 records (12.6%) and meta-analyses for 0. Randomized controlled trials number 5 (0.1%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 2,093 |
| 2000-2009 | 1,379 |
| 2010-2019 | 2,020 |
| 2020 onward | 998 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 820 | 12.6% |
| Meta-analyses | 0 | 0.0% |
| Randomized controlled trials | 5 | 0.1% |
Method: PubMed query "Ectodermal Dysplasia"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in rare and inherited diseases
Rare conditions are difficult to study: few patients means small studies, case reports and registries are common, and randomized trials are the exception. Small samples limit precision and can exaggerate effects, and cases reported in the literature may be the most severe or unusual. Evidence from many small studies is best read together. Check how patients were identified, how many were included and how long they were followed.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation | 2017 | Research article Design not recorded in structured metadata | 120 | cc by PMID 28589954 · DOI · PMC5467248 |
| Elucidating the genetic architecture of Adams-Oliver syndrome in a large European cohort | 2018 | Research article Design not recorded in structured metadata | 44 | cc by PMID 29924900 · DOI · PMC6175364 |
| Expansion of the phenotypic spectrum and description of molecular findings in a cohort of patients with oculocutaneous mosaic RASopathies | 2019 | Research article Design not recorded in structured metadata | 44 | cc by PMID 30891959 · DOI · PMC6503218 |
| Assessing healthcare experiences and barriers to care among individuals with ectodermal dysplasia | 2026 | Research article Design not recorded in structured metadata | 0 | cc by PMID 41787517 · DOI · PMC13072512 |
WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Human WNT10A mutations are associated with developmental tooth abnormalities and adolescent onset of a broad range of ectodermal defects.
- Closing excerpt
- Our data identify WNT10A as a critical ligand controlling adult epithelial proliferation and region-specific differentiation, and suggest downstream β-catenin pathway activation as a potential approach to ameliorate regenerative defects in WNT10A patients.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (146 words)
Human WNT10A mutations are associated with developmental tooth abnormalities and adolescent onset of a broad range of ectodermal defects. Here we show that β-catenin pathway activity and adult epithelial progenitor proliferation are reduced in the absence of WNT10A, and identify Wnt-active self-renewing stem cells in affected tissues including hair follicles, sebaceous glands, taste buds, nails and sweat ducts. Human and mouse WNT10A mutant palmoplantar and tongue epithelia also display specific differentiation defects that are mimicked by loss of the transcription factor KLF4. We find that β-catenin interacts directly with region-specific LEF/TCF factors, and with KLF4 in differentiating, but not proliferating, cells to promote expression of specialized keratins required for normal tissue structure and integrity. Our data identify WNT10A as a critical ligand controlling adult epithelial proliferation and region-specific differentiation, and suggest downstream β-catenin pathway activation as a potential approach to ameliorate regenerative defects in WNT10A patients.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 28589954 · DOI · PMC5467248
Elucidating the genetic architecture of Adams-Oliver syndrome in a large European cohort [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Adams-Oliver syndrome (AOS) is a rare developmental disorder, characterized by scalp aplasia cutis congenita (ACC) and transverse terminal limb defects (TTLD).
- Closing excerpt
- This cohort offers potential for further gene identification to address missing heritability.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (198 words)
Adams-Oliver syndrome (AOS) is a rare developmental disorder, characterized by scalp aplasia cutis congenita (ACC) and transverse terminal limb defects (TTLD). Autosomal dominant forms of AOS are linked to mutations in ARHGAP31, DLL4, NOTCH1 or RBPJ, while DOCK6 and EOGT underlie autosomal recessive inheritance. Data on the frequency and distribution of mutations in large cohorts are currently limited. The purpose of this study was therefore to comprehensively examine the genetic architecture of AOS in an extensive cohort. Molecular diagnostic screening of 194 AOS/ACC/TTLD probands/families was conducted using next-generation and/or capillary sequencing analyses. In total, we identified 63 (likely) pathogenic mutations, comprising 56 distinct and 22 novel mutations, providing a molecular diagnosis in 30% of patients. Taken together with previous reports, these findings bring the total number of reported disease variants to 63, with a diagnostic yield of 36% in familial cases. NOTCH1 is the major contributor, underlying 10% of AOS/ACC/TTLD cases, with DLL4 (6%), DOCK6 (6%), ARHGAP31 (3%), EOGT (3%), and RBPJ (2%) representing additional causality in this cohort. We confirm the relevance of genetic screening across the AOS/ACC/TTLD spectrum, highlighting preliminary but important genotype-phenotype correlations. This cohort offers potential for further gene identification to address missing heritability.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 29924900 · DOI · PMC6175364
Expansion of the phenotypic spectrum and description of molecular findings in a cohort of patients with oculocutaneous mosaic RASopathies [3]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundPostzygotic KRAS, HRAS, NRAS, and FGFR1 mutations result in a group of mosaic RASopathies characterized by related developmental anomalies in eye, skin, heart, and brain.
- Closing excerpt
- ConclusionOur study allowed the expansion of the clinical spectrum of mosaic RASopathies and supports that mosaicism for recurrent mutations in KRAS and FGFR1 is a commonly involved mechanism in these rare oculocutaneous anomalies.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (201 words)
BackgroundPostzygotic KRAS, HRAS, NRAS, and FGFR1 mutations result in a group of mosaic RASopathies characterized by related developmental anomalies in eye, skin, heart, and brain. These oculocutaneous disorders include oculoectodermal syndrome (OES) encephalo-cranio-cutaneous lipomatosis (ECCL), and Schimmelpenning-Feuerstein-Mims syndrome (SFMS). Here, we report the results of the clinical and molecular characterization of a novel cohort of patients with oculocutaneous mosaic RASopathies.MethodsTwo OES, two ECCL, and two SFMS patients were ascertained in the study. In addition, two subjects with unilateral isolated epibulbar dermoids were also enrolled. Molecular analysis included PCR amplification and Sanger sequencing of KRAS, HRAS, NRAS, and FGFR1 genes in DNA obtained from biopsies (skin/epibulbar dermoids), buccal mucosa, and blood leukocytes. Massive parallel sequencing was employed in two cases with low-level mosaicism.ResultsIn DNA from biopsies, mosaicism for pathogenic variants, including KRAS p.Ala146Thr in two OES subjects, FGFR1 p.Asn546Lys and KRAS p.Ala146Val in ECCL patients, and KRAS p.Gly12Asp in both SFMS patients, was demonstrated. No mutations were shown in DNA from conjunctival lesions in two subjects with isolated epibubar dermoids.ConclusionOur study allowed the expansion of the clinical spectrum of mosaic RASopathies and supports that mosaicism for recurrent mutations in KRAS and FGFR1 is a commonly involved mechanism in these rare oculocutaneous anomalies.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30891959 · DOI · PMC6503218
Assessing healthcare experiences and barriers to care among individuals with ectodermal dysplasia [4]
Abstract reading summary — source excerpts
- Opening excerpt
- PURPOSE: To conduct a scoping assessment of barriers and facilitators to medical and dental care among individuals and caregivers affected by ectodermal dysplasia (ED).
- Closing excerpt
- Fostering skills of self-advocacy among families and encouraging deliberative patient-provider relationships in healthcare education hold promise for improving rare disease care.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (252 words)
PURPOSE: To conduct a scoping assessment of barriers and facilitators to medical and dental care among individuals and caregivers affected by ectodermal dysplasia (ED). METHODS: A sequential quantitative and qualitative approach was employed using web-based questionnaires and focus groups. A 76-item questionnaire was developed using a combination of validated instruments and expert opinion. Sections included diagnosis, insurance coverage, oral health status, and access to care. Descriptive statistics and bivariate methods were used to compare medical versus dental access to and satisfaction with care. Focus groups were conducted using a semi-structured guide with caregivers of affected children and individuals with ED. Interview recordings were transcribed verbatim, coded, and analyzed inductively using MaxQDA software. RESULTS: A total of 174 questionnaire responses were received. Access to and satisfaction with dental care was lower than medical care. Subjects reported finances as the largest barrier to dental care. Eight focus groups were conducted. Most frequently cited frustrations included insurance delays or denials, dismissive provider attitudes, and fragmented coordination of care, all of which placed a time-intensive burden on the affected individual or caregiver. Self-advocacy was common and necessary in accessing proper resources. Families valued the sense of community gained from support organizations and interactions with other affected individuals. CONCLUSIONS: Effective providers demonstrate empathy, curiosity, and willingness to collaborate with their patients and other specialists. Families seek providers who demonstrate honesty, active listening, and open-mindedness to learn. Fostering skills of self-advocacy among families and encouraging deliberative patient-provider relationships in healthcare education hold promise for improving rare disease care.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41787517 · DOI · PMC13072512
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article The many faces of PHACE syndrome [5]
- Research article PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations [6]
- Research article Infantile hemangioma. Part 1: Epidemiology, pathogenesis, clinical presentation and assessment [7]
- Research article Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines [8]
- Research article Ellis-van Creveld syndrome [9]
- Research article Clinical and pathological features of pachyonychia congenita [10]
References
- Xu M, Horrell J, Snitow M, Cui J, Gochnauer H, Syrett CM, et al.. WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation. . 2017. PMID 28589954 · DOI · PMC5467248
- Meester JAN, Sukalo M, Schröder KC, Schanze D, Baynam G, Borck G, et al.. Elucidating the genetic architecture of Adams-Oliver syndrome in a large European cohort. . 2018. PMID 29924900 · DOI · PMC6175364
- Chacon-Camacho OF, Lopez-Moreno D, Morales-Sanchez MA, Hofmann E, Pacheco-Quito M, Wieland I, et al.. Expansion of the phenotypic spectrum and description of molecular findings in a cohort of patients with oculocutaneous mosaic RASopathies. . 2019. PMID 30891959 · DOI · PMC6503218
- Swanson AK, Hammersmith KJ, Peng J, Kramer KK, Wapner A, Meyer BD. Assessing healthcare experiences and barriers to care among individuals with ectodermal dysplasia. . 2026. PMID 41787517 · DOI · PMC13072512
- Metry DW, Dowd CF, Barkovich AJ, Frieden IJ. The many faces of PHACE syndrome. J Pediatr. 2001. PMID 11445804 · DOI
- Garzon MC, Epstein LG, Heyer GL, Frommelt PC, Orbach DB, Baylis AL, et al.. PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations. J Pediatr. 2016. PMID 27659028 · DOI · PMC6599593
- Rodríguez Bandera AI, Sebaratnam DF, Wargon O, Wong LF. Infantile hemangioma. Part 1: Epidemiology, pathogenesis, clinical presentation and assessment. J Am Acad Dermatol. 2021. PMID 34419524 · DOI
- Pierpont ME, Magoulas PL, Adi S, Kavamura MI, Neri G, Noonan J, et al.. Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines. Pediatrics. 2014. PMID 25180280 · DOI · PMC4179092
- Baujat G, Le Merrer M. Ellis-van Creveld syndrome. Orphanet J Rare Dis. 2007. PMID 17547743 · DOI · PMC1891277
- Leachman SA, Kaspar RL, Fleckman P, Florell SR, Smith FJ, McLean WH, et al.. Clinical and pathological features of pachyonychia congenita. J Investig Dermatol Symp Proc. 2005. PMID 16250204 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.